Original article: general thoracicNodal stage after induction therapy for stage IIIA lung cancer determines patient survival
Section snippets
Patients and methods
To identify all patients with stage IIIA NSCLC, a retrospective chart review was conducted on patients operated upon by members of the Division of Thoracic Surgery at Brigham and Women’s Hospital. A major question addressed in this study concerns the relevance of nodal status after induction therapy to patient prognosis after surgery. To answer this question, we limited our analysis only to patients who had been surgically staged as IIIA, underwent induction therapy followed by complete
Results
There were 44 women and 59 men in the group. The median age was 59 years (range 37 to 82 years). Twenty-nine patients were discovered to have lung cancer on a routine or a preoperative chest radiograph. Twenty-three patients presented with a cough, and 17 patients presented with hemoptysis. The rest of the patients presented with a variety of complaints including dyspnea, malaise, weight-loss, fever, pneumonia, and chest pain. Most patients were current or former smokers; however, 8 patients
Comment
In our retrospective review, we examined the outcome of a large number of patients who presented with N2-positive stage IIIA NSCLC and were treated with induction therapy followed by surgical resection. In this analysis, we focused only on completely resected patients because that was the only group for which complete pathological data are available. Unlike the patients in other series, all our patients were surgically staged with mediastinoscopy and biopsy of multiple nodal stations. All
Acknowledgements
We thank Elizabeth Allred for statistical analysis and Mary Visciano for editorial assistance.
References (16)
Revisions in the international system for staging lung cancer
Chest
(1997)The significance of ipsilateral mediastinal lymph node metastasis (N2 disease) in non-small cell carcinoma of the lunga commentary
J Thorac Cardiovasc Surg
(1990)- et al.
Results of Cancer and Leukemia Group B Protocol 8935a multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer
J Thorac Cardiovasc Surg
(1995) - et al.
Prognosis and survival in resected lung carcinoma based on the new international staging system
J Thorac Cardiovasc Surg
(1988) - et al.
Preoperative chemotherapy for stage IIIa (N2) lung cancerthe Sloan-Kettering experience with 136 patients
Ann Thorac Surg
(1993) - et al.
Induction chemotherapy before surgery for early-stage lung cancera novel approach
J Thorac Cardiovasc Surg
(2000) - et al.
Cancer statistics, 2000
CA Cancer J Clin
(2000) Combined modality therapy of lung cancer
Clin Cancer Res
(1997)
Cited by (225)
Tumor response evaluation by combined modalities of chest magnetic resonance imaging and computed tomography in locally advanced non-small cell lung cancer after concurrent chemoradiotherapy
2022, Radiotherapy and OncologyCitation Excerpt :Recently, MRI-linac guided adaptive radiotherapy has been applied in thoracic cancer, and the current study offered valuable information for monitoring lung tumor changes with multi-sequence MRI images. It has been consistently found that higher response rates can be achieved in the lymph nodes than in the primary tumor region among LA-NSCLC patients treated by neoadjuvant CCRT [40–42]. Based on the data from NCDB, only 13.2% of LA-NSCLC patients who had pCR in the primary tumor were accompanied by residual malignant lymph nodes [7].
PET imaging of lung and pleural cancer
2022, Nuclear Medicine and Molecular Imaging: Volume 1-4